Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290062 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Insmed Gene Therapy.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT07290062 is a Phase 1 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Insmed Gene Therapy. The registered enrollment target is 23 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07290062, a Phase 1 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Insmed Gene Therapy.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
Conditions Studied
Interventions
- GENETIC INS1202
Study Locations (3)
Missouri
- USA001 - Columbia
Ohio
- USA007 - Columbus
Pennsylvania
- USA006 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07290062
The ClinicalTrials.gov registry entry for NCT07290062 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Insmed Gene Therapy, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which INS1202 is the first listed.
NCT07290062 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Missouri, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07290062 about?
NCT07290062 is a clinical study titled "A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)". The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genet...
What is the current status of trial NCT07290062?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2026-01-09. Estimated completion is 2030-03-31.
What conditions does trial NCT07290062 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT07290062?
The interventions under investigation include: INS1202 (GENETIC).
Who is sponsoring clinical trial NCT07290062?
This trial is sponsored by Insmed Gene Therapy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290062 being conducted?
This trial has 3 study locations across Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
Regulatory T Cells for Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.